$1.38
0[0.00%]
At close: Apr 26
$1.38
0[0.00%]
After Hours: 6:41PM EDT
Context Therapeutics
(NASDAQ:CNTX)Context Therapeutics Stock (NASDAQ:CNTX), Analyst Ratings, Price Targets, Predictions
Context Therapeutics Inc has a consensus price target of $6, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Maxim Group on March 21, 2024, November 1, 2023, and September 11, 2023. With an average price target of $4.33 between HC Wainwright & Co., HC Wainwright & Co., and Maxim Group, there's an implied 214.01% upside for Context Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
ThinkEquity
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Context Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/21/2024 | CNTX | Buy Now | Context Therapeutics | $1.38 | 189.86% | HC Wainwright & Co. | Emily Bodnar | $5 → $4 | Maintains | Buy | Get Alert |
| 11/01/2023 | CNTX | Buy Now | Context Therapeutics | $1.38 | 262.32% | HC Wainwright & Co. | Emily Bodnar | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 09/11/2023 | CNTX | Buy Now | Context Therapeutics | $1.38 | 189.86% | Maxim Group | Jason McCarthy | → $4 | Initiates | → Buy | Get Alert |
| 06/06/2023 | CNTX | Buy Now | Context Therapeutics | $1.38 | — | HC Wainwright & Co. | Emily Bodnar | — | Reiterates | → Neutral | Get Alert |
| 03/23/2023 | CNTX | Buy Now | Context Therapeutics | $1.38 | — | HC Wainwright & Co. | Emily Bodnar | — | Downgrade | Buy → Neutral | Get Alert |
| 02/07/2023 | CNTX | Buy Now | Context Therapeutics | $1.38 | 189.86% | HC Wainwright & Co. | Emily Bodnar | → $4 | Reiterates | → Buy | Get Alert |
| 02/02/2022 | CNTX | Buy Now | Context Therapeutics | $1.38 | 334.78% | HC Wainwright & Co. | Emily Bodnar | → $6 | Initiates | → Buy | Get Alert |
| 01/24/2022 | CNTX | Buy Now | Context Therapeutics | $1.38 | 624.64% | ThinkEquity | Ashok Kumar | → $10 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Context Therapeutics (CNTX)?
The latest price target for Context Therapeutics (NASDAQ: CNTX) was reported by HC Wainwright & Co. on March 21, 2024. The analyst firm set a price target for $4.00 expecting CNTX to rise to within 12 months (a possible 189.86% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Context Therapeutics (CNTX)?
The latest analyst rating for Context Therapeutics (NASDAQ: CNTX) was provided by HC Wainwright & Co., and Context Therapeutics maintained their buy rating.
When was the last upgrade for Context Therapeutics (CNTX)?
The last upgrade for Context Therapeutics Inc happened on November 1, 2023 when HC Wainwright & Co. raised their price target to $5. HC Wainwright & Co. previously had a neutral for Context Therapeutics Inc.
When was the last downgrade for Context Therapeutics (CNTX)?
The last downgrade for Context Therapeutics Inc happened on March 23, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Context Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Context Therapeutics (CNTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Context Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Context Therapeutics was filed on March 21, 2024 so you should expect the next rating to be made available sometime around March 21, 2025.
Is the Analyst Rating Context Therapeutics (CNTX) correct?
While ratings are subjective and will change, the latest Context Therapeutics (CNTX) rating was a maintained with a price target of $5.00 to $4.00. The current price Context Therapeutics (CNTX) is trading at is $1.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.